Skip to main content
Clinical Trials/IRCT20170822035834N2
IRCT20170822035834N2
Not yet recruiting
Phase 2

Pilot Study of the Efficacy of Metformin as an Adjuvant Therapy in Patients with Pemphigus Vulgaris

Sari University of Medical Sciences0 sites40 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Condition 1: Pemphigus Vulgaris. Condition 2: Pemphigus foliaceus.
Sponsor
Sari University of Medical Sciences
Enrollment
40
Status
Not yet recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Sari University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • People diagnosed with their disease, and clinical manifestations and laboratory findings related to pemphigus (skin manifestations, etc.) have been proven by a dermatologist. And hospitalized in the relevant department.
  • Individual consent to participate in the study
  • age more than 18

Exclusion Criteria

  • age less than 18
  • Duration of diagnosis is more than 24 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistanceKlinische Pilotstudie zur Untersuchung der Wirkung von Metformin bei adipösen Kindern und Jugendlichen mit Insulin-Resistenz (IR) - not availableInsuline-resistance in adipose children and adolescents
EUCTR2004-003816-47-DEPädiatrische Endokrinologie, Universitätsmedizin Berlin, Charité
Recruiting
Phase 3
Impact of metformin on pregnancy outcomes in overweight womePregnancy outcomes in overweight pregnancies.
IRCT20190716044229N1Oroumia University of Medical Sciences350
Active, not recruiting
Not Applicable
A Prospective Randomised Pilot Study of Metformin and Lifestyle Intervention in the Prevention of Metabolic Syndrome due to Androgen Deprivation Therapy in Prostate Cancer - Metformin use in patients on ADT to prevent Metabolic SyndromePatients with prostate cancer on androgen deprivation therapy (ADT). Randomisation between standard treatment with ADT only, and the additional use of metformin with dietary and exercise advice.Aim is to reduce the prevalence of metabolic syndrome in the intervention arm - this is a condition linked to ADT in prostate cancer patientsMedDRA version: 9.1Level: LLTClassification code 10001186Term: Adenocarcinoma of prostateMedDRA version: 9.1Level: LLTClassification code 10052066Term: Metabolic syndrome
EUCTR2007-002815-20-GBRoyal Surrey County Hospital
Not yet recruiting
Phase 2
Metformin in the prevention of preeclampsiapreeclampsia.Pre-eclampsia
IRCT20230730058975N1Esfahan University of Medical Sciences160
Recruiting
Phase 2
An assessment of the use of metformin in preventing prednisone-induced elevation in blood glucose levels among blood cancer patients at Kenyatta National Hospital
PACTR201807745027158ucy Ochola50